Clinical Trial

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-14; most recent amendment 2026-03-03.
Status change: Not Yet Recruiting → Recruiting 2026-02-06
Trial Details
NCT Number NCT07217678
Lead Sponsor University of Miami
Collaborators: AbbVie
Conditions Glaucoma, Open-Angle Glaucoma, Ocular Hypertension, Glaucoma Suspect
Enrollment 20 participants
Start Date 2026-02-09
Primary Completion 2028-01-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-05